Thus, we herein analyzed the changes in QTc and IL-6 levels that occurred in patients with COVID-19 during the active disease and recovery phase, also making efforts to remove potential confounding effects due to concomitant QT-prolonging risk factors, pharmacological and non-pharmacological, and acute cardiac involvement. The gene discussed is IL6; the disease is COVID-19.